Get started
Catalyst Pharmaceuticals, Inc.Catalyst Pharmaceuticals, Inc.Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsOptionsETFs

CPRX chart


Full chart

CPRX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.42 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
12.00
Basic EPS (TTM)
1.73 USD
Net income (FY)
‪163.89 M‬ USD
Revenue (FY)
‪491.73 M‬ USD
Shares float
‪111.42 M‬
Beta (1Y)
0.66

Employees


Employees (FY)
181
Change (1Y)
+14 +8.38%
Revenue / Employee (1Y)
‪2.72 M‬ USD
Net income / Employee (1Y)
‪905.46 K‬ USD

About Catalyst Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Richard John Daly
Website
catalystpharma.com
Headquarters
Coral Gables
Founded
2002
ISIN
US14888U1016
FIGI
BBG000GZDC67
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Check out other big names from the same industry as CPRX.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CPRX news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CPRX is 19.70 USD — it has decreased by −1.35% in the past 24 hours. Watch Catalyst Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Catalyst Pharmaceuticals, Inc. stocks are traded under the ticker CPRX.
CPRX stock hasn't changed in a week, the month change is a −4.54% fall, over the last year Catalyst Pharmaceuticals, Inc. has showed a −4.69% decrease.
We've gathered analysts' opinions on Catalyst Pharmaceuticals, Inc. future price: according to them, CPRX price has a max estimate of 40.00 USD and a min estimate of 31.00 USD. Watch CPRX chart and read a more detailed Catalyst Pharmaceuticals, Inc. stock forecast: see what analysts think of Catalyst Pharmaceuticals, Inc. and suggest that you do with its stocks.
CPRX reached its all-time high on Jun 9, 2025 with the price of 26.58 USD, and its all-time low was 0.37 USD and was reached on Nov 13, 2012. View more price dynamics on CPRX chart.
See other stocks reaching their highest and lowest prices.
CPRX stock is 2.46% volatile and has beta coefficient of 0.66. Track Catalyst Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Catalyst Pharmaceuticals, Inc. there?
Today Catalyst Pharmaceuticals, Inc. has the market capitalization of ‪2.42 B‬, it has decreased by −1.14% over the last week.
Yes, you can track Catalyst Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Catalyst Pharmaceuticals, Inc. is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
CPRX earnings for the last quarter are 0.41 USD per share, whereas the estimation was 0.39 USD resulting in a 4.59% surprise. The estimated earnings for the next quarter are 0.33 USD per share. See more details about Catalyst Pharmaceuticals, Inc. earnings.
Catalyst Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪146.54 M‬ USD, despite the estimated figure of ‪140.44 M‬ USD. In the next quarter, revenue is expected to reach ‪136.77 M‬ USD.
CPRX net income for the last quarter is ‪52.11 M‬ USD, while the quarter before that showed ‪56.74 M‬ USD of net income which accounts for −8.16% change. Track more Catalyst Pharmaceuticals, Inc. financial stats to get the full picture.
No, CPRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 25, 2025, the company has 181 employees. See our rating of the largest employees — is Catalyst Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Catalyst Pharmaceuticals, Inc. EBITDA is ‪281.39 M‬ USD, and current EBITDA margin is 47.42%. See more stats in Catalyst Pharmaceuticals, Inc. financial statements.
Like other stocks, CPRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Catalyst Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Catalyst Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Catalyst Pharmaceuticals, Inc. stock shows the neutral signal. See more of Catalyst Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.